The present invention relates to the use of a composition comprising a synergistic combination of (a) at least one reduced isoalpha acid compound selected from the group consisting of dihydro-isohumulone, dihydro-isocohumulone, dihydro-isoadhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone, tetrahydro-isoadhumulone, hexahydro-isohumulone, hexahydro-isocohumulone, and hexahydro-isoadhumulone, (b) at least one mineral, and (c) at least one vitamin for the manufacture of a medicament for the treatment of an autoimmune disease in a mammal； wherein the combination of (a), (b) and (c) provides a combination index (CI) of less than 1 for synergistic inhibition of PGE2 production.
